Openbookopenbook
Equity
SIGA Technologies Inc(SIGA)
USD --+0.00%
Reward65Moderate
Risk23Low
📊75%Data
Strong 43% profit margin · Revenue down 74% YoY
SIGA
+0.0 · +0.00%
USD · NASDAQ
SIGA Technologies Inc | Healthcare
Deep Value
Market Cap:463.33M
ℹ️
Reward Rating
65
Moderate
Top 50% (model universe)
75% data coverage
ℹ️
Risk Rating
23
Low
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on SIGA to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $17.53.

What is SIGA Technologies Inc?

, a commercial-stage pharmaceutical company, focuses on the health security market in the United States.

SIGA · Verdict

Solid reward · low risk

SIGA scores well on valuation and balance sheet with no major weaknesses flagged in the model.

Based on 88% data coverage

SIGA · Verdict

What’s working & what to watch

Strengths 4

  • Valuation100/100

    P/E 4.5× · PEG 0.02

  • Balance sheet100/100

    Current ratio 9.12

  • Cash flow86/100

    35% free-cash-flow margin

  • Profitability81/100

    43% net margin · 40% ROE

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is SIGA Technologies Inc?

, a commercial-stage pharmaceutical company, focuses on the health security market in the United States. Its lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 463.33M, and a P/E ratio of 6.3x.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Strong margins and consistent earnings support financial stability.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Currently trading below intrinsic value estimates, suggesting upside potential.

OpenBook Logo Analysis

Reward: Moderate (65)

The scoring profile indicates moderate reward potential, with valuation and profitability as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap463.33M
P/E Ratio6.2816
Dividend YieldN/A
52 Week High9.62
52 Week Low4.4823
Last AnnualDecember
IPO Date9/9/1997
IncorporatedUSA
Shares Outstanding72M
No. of Employees46
IndustryDrug Manufacturers - Specialty & Generic
ExchangeNASDAQ
Beta0.981
CurrencyUSD
Websitewww.siga.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.